Table 1 Patient and tumor characteristics
From: Leptin/HER2 crosstalk in breast cancer: in vitro study and preliminary in vivoanalysis
Clinicopathological Features | Patients n (%) | Clinicopathological Features | Patients n (%) |
|---|---|---|---|
Menopausal status | Â | T | Â |
Postmenopausal | 15 (25) | TIS | 3 (5) |
Premenopausal | 39 (66) | pTx | 1 (2) |
Unknown | 5 (9) | pT1 | 19 (33) |
Histotype | Â | pT2 | 22 (37) |
Ductal invasive | 45 (76) | pT3 | 2 (3) |
Lobular invasive | 4 (7) | pT4 | 12 (20) |
Intraductal | 3 (5) | Diameter (mm) | Â |
Inflammatory | 4 (7) | ≤ 10 mm | 9 (15) |
Other | 3 (5) | > 10 mm | 42 (71) |
Grading | Â | Unknown | 8 (14) |
G1 | 7 (12) | Â | Â |
G2 | 18 (31) | N | Â |
G3 | 26 (44) | pN1-3 | 20 (34) |
Unknown | 8 (13) | pN4-10 | 9 (15) |
Ki-67 | Â | pN > 10 | 4 (7) |
0–15% | 33 (56) | Negative | 19 (32) |
16–25% | 9 (15) | Unknown | 7 (12) |
26–100% | 14 (24) | HER-2 |  |
Unknown | 3 (5) | Positive | 31 (53) |
ER/PgR | Â | Negative | 28 (47) |
ER+/PgR+ | 38 (64) | Â | Â |
ER-/PgR- | 12 (20) | LVI | Â |
ER+/PgR- | 7 (12) | Positive | 27 (46) |
ER-/PgR+ | 1 (2) | Negative | 24 (41) |
Unknown | 1 (2) | Unknown | 8 (13) |